Skip to main content
Premium Trial:

Request an Annual Quote

Millipore Looks to Expand Cell-Based Assay Play with Launch of GPCR Screening Service

Pulling together technologies that had been developed in house and from its recent acquisition of Serologicals, Millipore this week bolstered its presence in the cell-based assay field with the launch of a GPCR screening service.
Millipore had been “slowly developing” its GPCR product portfolio over the past couple of years, a company official told Cell-Based Assay News, but the technologies it acquired along with Serologicals earlier this year enabled the firm to roll out what it believes is the most complete functional cell-based assay platform on the market.
“Nobody’s currently offering this complete functional service that we provide,” said Theresa Schaub, product manager for the service, called GPCRProfiler.
The firm believes that the GPCRProfiler screening service more accurately characterizes lead compounds than traditional binding methods by providing more comprehensive functional data.
According to Schaub, the service is “a complete and total product package. We offer three different services: profiling, screening, and dose-response. Also, we have membrane preps, cell lines for licensing, and we do develop custom cell lines for clients.”
She told Cell-Based Assay News that the firm had “developed a system that allows our customers to look at any GPCR through calcium mobilization, and that’s unique.Pretty much every person in pharma is going to have an instrument that can measure calcium mobilization or flux.” So, the market for its GPCR screening service should be fairly large.
Company officials would not disclose pricing of the GPCRProfiler service.
GPCRs are among the most prominent targets in drug discovery, along with kinases and ion channel cell lines. Industry participants have said GPCR screening is a rapidly growing field, and Millipore estimates that GPCRs comprise more than 40 percent of drug screening programs and are targets for more than 50 percent of currently marketed pharmaceuticals.
The market has attracted many tool vendors, including PerkinElmer, Invitrogen, DiscoverX, and Cisbio. Molecular Devices’ FLIPR platform is thought to be the market leader for GPCR and ion channel screening — and it is the instrument used in Millipore’s GPCRProfiler service.
According to Schaub, a key advantage for the firm’s GPCRProfiler service is that after a first round of screening, “we can tell our customers whether or not they have an agonist- or an antagonist-acting compound.
“The way FLIPR works is you can measure whether you are actually stimulating the receptor or inhibiting the receptor,” she said. “Most other services, what they do is just measure whether or not your compound binds to the receptor. We actually say, ‘Not only does the compound bind, but this is what it does.’ We’re the only one to do that.”
According to Schaub, Millipore’s GPCR product portfolio is “relatively new. We’ve been in the business maybe two years, but have been very slowly developing our product line and our product portfolio. For the past six months, the cell lines and the membranes are something we’ve really been promoting,” she said.
Schaub noted that the service uses a common assay platform that simplifies data comparison and allows for correlating current data with historical data.
She said Millipore did a “small beta test” on the screening service before the launch, and it has customers already using the service, though Schaub did not name any of these clients. However, she did say that they are primarily pharma and biotech company researchers.
The GPCRProfiler service was partially enabled by the company’s Chemiscreen technology, which funnels all GPCR signaling through real-time calcium mobilization. Millipore gained the Chemiscreen technology through its $1.4-billion acquisition of Serologicals earlier this year.
According to Schaub, there are roughly 500 relevant GPCR targets that have been discovered, and Millipore currently has more than 100 for profiling and screening. “We’re looking to have 185 by the end of next year,” she said. “We feel that will represent what most people are interested in.”

A key advantage for the firm’s GPCRProfiler service is that after a first round of screening, “we can tell our customers whether or not they have an agonist- or an antagonist-acting compound.”

The firm’s GPCR portfolio also includes filtration plates for looking at membrane-binding assays, said Schaub.
The service is being detailed by the firm’s generalized sales force, which is organized by region, not by product type, a Millipore spokesperson said. Following the acquisition of Serologicals, Millipore said it would have a worldwide sales, sales support, and service staff of roughly 1,200 people.
In addition to GPCR screening services and technologies, Millipore gained a portfolio of ion channel cell lines and related screening services when it acquired Serologicals. Those capabilities had been acquired by Serologicals earlier this year when it purchased Cytomyx Ltd. for $7 million (see CBA News 3/17/2006).
The Millipore spokesperson said the firm offers similar services to the GPCRProfiler for ion channel and kinase screening, but those services do not use Molecular Devices’ FLIPR platform.

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.